So, given the background how are the innovator companies tackling the generics rush. For one, many of these innovator companies are diversifying with generics themselves and are scouting partners and acquisition targets.

Now, given that most of the generics drug approvals in Asia are with Indian companies India is the market that will witness high action with regard to mergers & acquisitions. Just last week, the news doing rounds was Merck is set to acquire Micro Labs, an API maker in India. Many other MNCs are scouting the market for a company that will boost its bottom line. In fact, this is the only way these MNCs can buy a couple of years of time to figure out their strategy ahead.

While all this action is happening, the real beneficiaries are patients across the globe, whose access to affordable generics drugs is improving and will improve further by leaps and bounds.

The pharmaceutical drugs pricing regime, globally, is set for a sea change.